Mark H. O'Hara, MD
Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
Department: Medicine
Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-306
3400 Civic Center Blvd
Philadelphia, PA 19104
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-306
3400 Civic Center Blvd
Philadelphia, PA 19104
Office: (215)360-0735
Fax: (215)662-4646
Fax: (215)662-4646
Education:
BS (Biology - Molecular Genetics)
University of Rochester, 2004.
MD (Medicine)
Stony Brook School of Medicine, 2008.
Permanent linkBS (Biology - Molecular Genetics)
University of Rochester, 2004.
MD (Medicine)
Stony Brook School of Medicine, 2008.
Description of Clinical Expertise
GI cancers, Phase 1 trials, Pancreatic cancer, Colorectal cancer, Anal cancer, Esophageal cancer, Gastric cancer, Hepatocellular carcinoma, Cholangiocarcinoma, Neuroendocrine tumorDescription of Research Expertise
Pancreatic cancer, colorectal cancer, GI cancers, Phase 1, CAR T cell therapySelected Publications
Than MT, O'Hara M, Stanger BZ, Reiss KA.: KRAS-Driven Tumorigenesis and KRAS-Driven Therapy in Pancreatic Adenocarcinoma. Molecular Cancer Therapeutics 23(10): 1378 - 1388, Oct 2024.O'Hara MH, Jegede O, Dickson MA, DeMichele AM, Piekarz R, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Onitilo A, Tricoli JV, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT.: Phase 2 Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol Z1. Clinical Cancer Research October 2024.
Hochster HS, Catalano P, Weitz M, Mitchell EP, Cohen D, O'Dwyer PJ, Faller BA, Kortmansky JS, O'Hara MH, Kricher SM, Lacy J, Lenz HJ, Verma U, Benson AB: Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer (ECOG-ACRIN E7208). J Natl Cancer Inst 6(9): 1487-1494, Sept 2024.
Bear AS, Nadler RB, O'Hara MH, Stanton KL, Xu C, Saporito RJ, Rech AJ, Baroja ML, Blanchard T, Elliott MH, Ford MJ, Jones R, Patel S, Brennan A, O'Neil Z, Powell DJ Jr, Vonderheide RH, Linette GP, Carreno BM.: Natural TCRs targeting KRASG12V display fine specificity and sensitivity to human solid tumors. J Clin Invest 134(21), Sept 2024.
Chapin WJ, Hwang WT, Mamtani R, O'Hara MH.: Low- vs High-Dose 5-FU in Triplet Chemotherapy Plus Bevacizumab for Patients With Colorectal Cancer. JAMA Netw Open 7(7), Jul 2024.
Till JE, McDaniel L, Chang C, Long Q, Pfeiffer SM, Lyman JP, Padrón LJ, Maurer DM, Yu JX, Spencer CN, Gherardini PF, Da Silva DM, LaVallee TM, Abbott C, Chen RO, Boyle SM, Bhagwat N, Cannas S, Sagreiya H, Li W, Yee SS, Abdalla A, Wang Z, Yin M, Ballinger D, Wissel P, Eads J, Karasic T, Schneider C, O'Dwyer P, Teitelbaum U, Reiss KA, Rahma OE, Fisher GA, Ko AH, Wainberg ZA, Wolff RA, O'Reilly EM, O'Hara MH, Cabanski CR, Vonderheide RH, Carpenter EL.: Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma. Nature Communications 15(1): 5763, July 2024.
Ban-Ami, R, Wang, QL, Zhang J, Supplee JG, Fahrmann JF, Lehmann-Werman R, Brais LK, Nowak J, Yuan C, Loftus M, Babic A, Irajizad E, Davidi T, Zick A, Hubert A, Neiman D, Piyanzin S, Gal-Rosenberg O, Horn A, Shemer R, Glaser B, Boos N, Jajoo K, Lee L, Clancy TE, Rubinson DA, Ng K, Chabot JA, Kastrinos F, Kluger M, Aguirre AJJ, Janne PA, Bardeesy N, Stanger B, O'Hara MH, Till J, Maitra A, Carpenter EL, Bullock AJ, Genkinger J, Hanash SM, Paweletz CP, Dor Y, Wolpin BM: Protein biomarkers and alternatively methylated cell-free DNA detect early stage pancreatic cancer. Gut 7(73): 639-648, March 2024.
Brown TJ, Yablonovitch A, Till JE, Yen J, Kiedrowski LA, Hood R, O'Hara MH, Teitelbaum U, Karasic TB, Schneider C, Carpenter EL, Nathanson K, Domchek SM, Reiss KA.: The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 After Progression on Rucaparib. Clinical Cancer Research 29(24): 5207-5216, Dec 2023.
Chapin WJ, Hwang WT, Mamtani R, O'Hara MH: Real-world comparison of triplet- versus doublet-chemotherapy with bevacizumab in patients with newly diagnosed metastatic colorectal cancer (mCRC). American Society of Clinical Oncology Annual Meeting, Chicago, IL. 41(suppl 16): abstract 3574, Jun 2023 Notes: "Poster Presentation"
O'Hara MH, Wattenberg MM, Garrido-Laguna I, O'Reilly EM, Yellin MJ, Keler T, Gargano MA, Niles N, Drees J, Bose N, Iglesias JL, Beatty GL: A phase 1b, open-label, two-part safety, tolerability, and efficacy study of a soluble beta-glucan (odetiglucan) in combination with a CD40 agonistic monoclonal antibody (CDX-1140) in patients with metastatic pancreatic adenocarcinoma whose disease did not progress during first-line (1L) chemotherapy. American Society of Clinical Oncology Annual Meeting, Chicago, IL. 41(suppl 16): TPS4201, Jun 2023 Notes: "Oral Presentation"